MXPA05012955A - Pharmaceutical compositions of atorvastatin. - Google Patents

Pharmaceutical compositions of atorvastatin.

Info

Publication number
MXPA05012955A
MXPA05012955A MXPA05012955A MXPA05012955A MXPA05012955A MX PA05012955 A MXPA05012955 A MX PA05012955A MX PA05012955 A MXPA05012955 A MX PA05012955A MX PA05012955 A MXPA05012955 A MX PA05012955A MX PA05012955 A MXPA05012955 A MX PA05012955A
Authority
MX
Mexico
Prior art keywords
atorvastatin
pharmaceutical composition
pharmaceutical compositions
compositions
dry
Prior art date
Application number
MXPA05012955A
Other languages
Spanish (es)
Inventor
Paul Evan Luner
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of MXPA05012955A publication Critical patent/MXPA05012955A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Abstract

A dry-granulated pharmaceutical composition comprising atorvastatin or a pharmaceutically acceptable salt thereof, as well as a dry-granulated pharmaceutical composition comprising atorvastatin or a pharmaceutically acceptable salt thereof in combination with at least one other active drug, methods for preparing said compositions, kits for containing such compositions, and a method of treating hypercholesterolemia and/or hyperlipidemia, osteoporosis, benign prostatic hyperplasia (BPH), and Alzheimer's disease using a therapeutically effective amount of the pharmaceutical composition.
MXPA05012955A 2003-06-12 2004-06-01 Pharmaceutical compositions of atorvastatin. MXPA05012955A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47791703P 2003-06-12 2003-06-12
PCT/IB2004/001859 WO2004110406A1 (en) 2003-06-12 2004-06-01 Pharmaceutical compositions of atorvastatin

Publications (1)

Publication Number Publication Date
MXPA05012955A true MXPA05012955A (en) 2006-02-13

Family

ID=33551780

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05012955A MXPA05012955A (en) 2003-06-12 2004-06-01 Pharmaceutical compositions of atorvastatin.

Country Status (15)

Country Link
EP (1) EP1635788A1 (en)
JP (1) JP2006527259A (en)
KR (1) KR100760112B1 (en)
CN (1) CN1805732A (en)
AR (1) AR044660A1 (en)
AU (1) AU2004246867A1 (en)
BR (1) BRPI0411354A (en)
CA (1) CA2465693A1 (en)
CO (1) CO5640071A2 (en)
MX (1) MXPA05012955A (en)
NO (1) NO20060149L (en)
RU (1) RU2325903C2 (en)
TW (1) TW200503689A (en)
WO (1) WO2004110406A1 (en)
ZA (1) ZA200508204B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE05810535T1 (en) * 2004-10-18 2007-04-19 Teva Pharmaceutical Industries Ltd. METHOD FOR THE PRODUCTION OF AMORPHIC ATORVASTATIN HEMI CALCIUM BY SOLVING THE SALT IN AN ORGANIC SOLVENT WHICH IS A MIXTURE OF ANES ALCOHOL AND A KETONE AND / OR ESTERS, AND REMOVING THE SOLVENT
CA2547216A1 (en) * 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
CN101415425B (en) * 2006-03-29 2014-11-26 兴和株式会社 Triglyceride-lowering agent and hyperinsulinism-ameliorating agent
CN102976996B (en) * 2009-05-27 2015-08-19 峡江和美药业有限公司 Atorvastatin semi strontium salt polymorphic form, its preparation and the application as HMG-CoA enzyme inhibitors
JP5714600B2 (en) 2009-12-18 2015-05-07 フリースランドカンピナ・ネーデルランド・ホールディング・ビー．ブイ．ＦｒｉｅｓｌａｎｄＣａｍｐｉｎａ Ｎｅｄｅｒｌａｎｄ Ｈｏｌｄｉｎｇ Ｂ．Ｖ． Co-processed tablet excipient mixture, its preparation and use
KR20120105035A (en) * 2009-12-22 2012-09-24 노파르티스 아게 Formulation comprising 1h-quinazoline-2,4-dione ampa receptor antagonists, in the form of immediate release tablets and preparation thereof
EP2575757A1 (en) 2010-06-03 2013-04-10 Mahmut Bilgic Water soluble formulation comprising a combination of amlodipine and a statin
EA018867B1 (en) * 2012-11-01 2013-11-29 Лаборатория Тютор С.А.С.И.Ф.И.А. Method of producing pharmaceutical composition and product therefrom
CN104825449A (en) * 2014-02-12 2015-08-12 天津药物研究院 Compound composition containing atorvastatin calcium and amlodipine and preparation method of same
EP3185056A4 (en) * 2014-09-26 2018-05-16 Fujikura, Ltd. Optical fiber
RU2591079C2 (en) * 2014-12-10 2016-07-10 Александр Владимирович Диковский Pharmaceutical composition of statins with prebiotic for therapy of hypercholesteremia and hyperlipidemia
WO2016198351A1 (en) * 2015-06-10 2016-12-15 Evonik Röhm Gmbh Process for preparing a powder comprising a human coagulation factor protein and a lactic acid polymer
US20180303799A1 (en) * 2015-10-16 2018-10-25 Shenzhen Salubris Pharmaceuticals Co., Ltd An Oral Preparation for the Treatment of Cardiovascular Disease and Its Preparation Method
CN117835971A (en) 2021-08-25 2024-04-05 巴斯夫欧洲公司 Adjuvant composition for direct compression
CN114674944A (en) * 2022-03-04 2022-06-28 苏州东瑞制药有限公司 Method for detecting related substances of amlodipine besylate and atorvastatin calcium compound preparation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE478665T1 (en) * 1999-11-17 2010-09-15 Teva Pharma METHOD FOR PRODUCING A POLYMORPHOUS FORM OF ATORVASTATIN CALCIUM
SI20848A (en) 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Pharmaceutical formulation containing atorvastatin calcium
CA2442280A1 (en) * 2001-03-27 2002-10-03 Ranbaxy Laboratories Limited A stable pharmaceutical composition of pravastatin
JP2003055217A (en) * 2001-08-10 2003-02-26 Taiyo Yakuhin Kogyo Kk Pharmaceutical composition
GB0121436D0 (en) * 2001-09-04 2001-10-24 Pfizer Ltd Biomodulated multiparticulate formulations
CA2385529A1 (en) * 2002-05-21 2003-11-21 Bernard Charles Sherman Stable dosage forms comprising atorvastatin calcium
AU2003283769A1 (en) * 2002-12-20 2004-07-14 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor

Also Published As

Publication number Publication date
ZA200508204B (en) 2007-03-28
BRPI0411354A (en) 2006-07-11
AR044660A1 (en) 2005-09-21
TW200503689A (en) 2005-02-01
AU2004246867A1 (en) 2004-12-23
CN1805732A (en) 2006-07-19
CO5640071A2 (en) 2006-05-31
JP2006527259A (en) 2006-11-30
NO20060149L (en) 2006-03-06
KR100760112B1 (en) 2007-09-18
WO2004110406A1 (en) 2004-12-23
KR20060025167A (en) 2006-03-20
RU2325903C2 (en) 2008-06-10
CA2465693A1 (en) 2004-12-12
EP1635788A1 (en) 2006-03-22
RU2005136743A (en) 2006-07-27

Similar Documents

Publication Publication Date Title
NO20060149L (en) Pharmaceutical compounds of atorvastatin
TW200509905A (en) Pharmaceutical compositions of atorvastatin
PL373903A1 (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
EP1562897A4 (en) Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer s disease
FR16C0021I2 (en) AZETIDINES AS MEK INHIBITORS AND THEIR USE FOR THE TREATMENT OF PROLIFERATIVE DISEASES
AU7031500A (en) Therapeutic quinazoline compounds
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
AP1818A (en) Urea-compounds active as vanilloid receptor antagonists for the treatment of pain
EP2305251A3 (en) Pharmaceutical compositions comprising clavulanic acid or derivative thereof for the treatment of sexual disorder
MXPA02011303A (en) Liquid pharmaceutical composition containing an erythropoietin derivate.
NO20060022L (en) Stable compositions of atorvastatin prepared by cotton granulation
RS49756B (en) Use of xenon for preparing a pharmaceutical preparation for treating neurointoxications
AU2002314914A1 (en) Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer's disease and similar diseases
ATE260658T1 (en) PHARMACEUTICAL PREPARATIONS FOR REDUCING RESPIRATORY DEPRESSION
MXPA05003253A (en) Novel pyrimidineamide derivatives and the use thereof.
ATE386725T1 (en) HETEROCYCLYL COMPOUNDS
AU2001290480A1 (en) Cyclized benzamide neurokinin antagonists for use in therapy
GB9907571D0 (en) Compounds
EP1031352A3 (en) Use of desmopressin in the preparation of a metastatic dissemination inhibitor medicament during cancer surgery
UA66932C2 (en) Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine
JO2199B1 (en) Substituted pyrroles
CA2426492A1 (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
HK1082727A1 (en) 2" oxo-voruscharin and derivatives thereof
WO2007063428A3 (en) Pharmaceutical compositions comprising carboxyalkylsulfonic acids
EP1408043A8 (en) 2''oxo-voruscharin and analogues thereof